Cargando…

Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial

BACKGROUND: For patients with pancreatic ductal adenocarcinoma (PDAC), surgical resection remains the only potentially curative treatment. Surgery is generally followed by postoperative chemotherapy associated with improved survival, yet neoadjuvant therapy is a rapidly emerging concept requiring to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bouchart, Christelle, Navez, Julie, Borbath, Ivan, Geboes, Karen, Vandamme, Timon, Closset, Jean, Moretti, Luigi, Demetter, Pieter, Paesmans, Marianne, Van Laethem, Jean-Luc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512504/ https://www.ncbi.nlm.nih.gov/pubmed/37735634 http://dx.doi.org/10.1186/s12885-023-11327-x

Ejemplares similares

Isotoxic High-Dose Stereotactic Body Radiotherapy (iHD-SBRT) Versus Conventional Chemoradiotherapy for Localized Pancreatic Cancer: A Single Cancer Center Evaluation
por: Manderlier, Martin, et al.
Publicado: (2022)

Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma
por: Bouchart, Christelle, et al.
Publicado: (2021)

Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer
por: Li, Xujia, et al.
Publicado: (2023)

The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study
por: Yang, Lei, et al.
Publicado: (2023)

Pegylated G-CSF Combined with mFOLFIRINOX for Advanced Pancreatic Cancer Patients
por: Chen, Peng, et al.
Publicado: (2019)

What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact?
por: Navez, Julie, et al.
Publicado: (2021)

Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution
por: Quan, Qi, et al.
Publicado: (2020)

Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?
por: Bouchart, Christelle, et al.
Publicado: (2020)

Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial
por: van Dam, J. L., et al.
Publicado: (2023)

Serum levels of IL-6 and CRP can predict the efficacy of mFOLFIRINOX in patients with advanced pancreatic cancer
por: Shen, Feifei, et al.
Publicado: (2022)

SMAD4 Positive Pancreatic Ductal Adenocarcinomas Are Associated with Better Outcomes in Patients Receiving FOLFIRINOX-Based Neoadjuvant Therapy
por: Racu, Marie-Lucie, et al.
Publicado: (2023)

Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S‐1 as second‐line chemotherapy in metastatic pancreatic cancer
por: Ikezawa, Kenji, et al.
Publicado: (2021)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Dose Escalation for Pancreas SBRT: Potential and Limitations of using Daily Online Adaptive Radiation Therapy and an Iterative Isotoxicity Automated Planning Approach
por: Rhee, Dong Joo, et al.
Publicado: (2023)

Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study
por: Yamao, Kentaro, et al.
Publicado: (2019)

Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study
por: Williet, Nicolas, et al.
Publicado: (2021)

Pancreatic Cancer Meets Human Microbiota: Close Encounters of the Third Kind
por: Arsenijevic, Tatjana, et al.
Publicado: (2021)

Multicentre, interventional, single-arm study protocol of telemonitored circadian rhythms and patient-reported outcomes for improving mFOLFIRINOX safety in patients with pancreatic cancer (MultiDom, NCT04263948)
por: Bouchahda, Mohamed, et al.
Publicado: (2023)

The impact of a multidisciplinary team approach on the management of focal pancreatic lesions: a single tertiary center experience
por: Francisse, Sophie, et al.
Publicado: (2023)

Reply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'
por: Pernot, Simon, et al.
Publicado: (2016)

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
por: Portal, Alix, et al.
Publicado: (2015)

Sex Differences in the Pathophysiology, Treatment, and Outcomes in IHD
por: Sanghavi, Monika, et al.
Publicado: (2015)

FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
por: Cho, In Rae, et al.
Publicado: (2020)

Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021)

Combination, Modulation and Interplay of Modern Radiotherapy with the Tumor Microenvironment and Targeted Therapies in Pancreatic Cancer: Which Candidates to Boost Radiotherapy?
por: Benkhaled, Sofian, et al.
Publicado: (2023)

CVVH versus IHD in patients with multiple organ failure
por: Gašparović, V, et al.
Publicado: (2003)

Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure
por: Hahn, Sarah, et al.
Publicado: (2017)

Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
por: Vogl, Ursula M., et al.
Publicado: (2019)

Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
por: Klein-Brill, Avital, et al.
Publicado: (2022)

Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
por: Di Costanzo, Francesco, et al.
Publicado: (2023)

Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy
por: Tong, Yi Tat, et al.
Publicado: (2023)

Response to the Letter to the Editor ‘Reply to “Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study” by Dr. Peng Chen’
por: Yamao, Kentaro, et al.
Publicado: (2019)

Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial
por: Assenat, E., et al.
Publicado: (2021)

Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study
por: Williet, Nicolas, et al.
Publicado: (2019)

Comment on: ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'
por: Vivaldi, Caterina, et al.
Publicado: (2016)

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
por: Sawada, Masashi, et al.
Publicado: (2020)

Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel
por: Sams, L., et al.
Publicado: (2021)

Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis
por: Lee, Yoon Suk, et al.
Publicado: (2021)

Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis
por: Ramaswamy, Anant, et al.
Publicado: (2023)

Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
por: Fukahori, Masaru, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_53bi714i0fb723t5p6mppjteut